Immunotherapy
Finding ways to stimulate the body's immune system to help attack cancer cells is a growing area of research at The Institute of Cancer Research.
Clinical trials led by the ICR and our hospital partner The Royal Marsden have shown that the immunotherapy drug pembrolizumab can help extend the lives of some patients with advanced head and neck cancer, and prostate cancer.
The use of 'oncolytic' viruses, which can kill cancer cells both directly and by directing the immune system against them, is also an exciting area of research being explored by ICR researchers.
This page highlights recent news stories, blog posts and videos that concern immunotherapy research at the ICR.
Related pages
Latest ICR News
-is-malignancy-of-the-esophagus-cancer-of-the-esophagus-ct-with-contrast.jpg?sfvrsn=70ef5f67_1 "Esophageal cancer (or oesophageal cancer) is malignancy of the esophagus. Cancer of the esophagus, CT with contrast.")
New study reveals how oesophageal cancer adapts to treatment
Researchers have tracked how the most common form of oesophageal cancer and its immune environment change during a standard form of treatment – offering vital clues that could shape future therapies, so they work for longer.
Newly discovered role of enzyme could explain link between diabetes and cancer
Cell biologists have made a significant advance, uncovering the key role of an enzyme in determining the physical structure and behaviour of cancer cells, including how they spread.